title: Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.
abstract: To compare the therapeutic effects of intensive versus moderate dosage of atorvastatin regimens in new-onset unstable angina with borderline lesions, 100 patients were randomized to receive either 80 mg/d or 20 mg/d atorvastatin for 9 months. Clinical symptoms, lipid profiles, and coronary stenosis (evaluated by coronary angiography and intravascular ultrasound) were compared to their corresponding baselines within each group and between the 2 groups after 9 months of treatment. The results showed that (1) when compared to their corresponding baselines, both groups exhibited improvement in clinical symptoms, a significant decrease in total cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), and high-sensitivity C-reactive protein (hs-CRP; P < .01) and a significant increase in high-density lipoprotein cholesterol (HDL-C); (2) the improvement in clinical symptoms and the decrease in LDL-C and hs-CRP were significantly greater (P < .01) in the intensive-dose group than in the moderate-dose group; (3) the mean plaque volume did not progress in the intensive-dose group but increased significantly (P < .05) in the moderate-dose group. We conclude that compared to the moderate dose, the intensive-dose regimen significantly improves clinical symptoms, lowers LDL-C and hs-CRP, and halts the progression of borderline atherosclerotic plaques in patients with new-onset unstable angina.
authors.affiliation: Graduate School, Ningxia Medical University, Ningxia, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.forename: Hairong
authors.initials: H
authors.lastname: Wang
authors.forename: Shanshan
authors.initials: S
authors.lastname: Liu
authors.forename: Peihua
authors.initials: P
authors.lastname: Gong
authors.forename: Jie
authors.initials: J
authors.lastname: Lin
authors.forename: Jide
authors.initials: J
authors.lastname: Lu
authors.forename: Jianping
authors.initials: J
authors.lastname: Qiu
authors.forename: Xiaojiong
authors.initials: X
authors.lastname: Lu
mesh_terms: D000368:Aged; D000789:Angina, Unstable / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D000069059:Atorvastatin; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006538:Heptanoic Acids / Q000008:administration & dosage*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D058226:Plaque, Atherosclerotic / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology*; D011446:Prospective Studies; D011758:Pyrroles / Q000008:administration & dosage*
chemical_list: D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin